Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab in Pediatric Ulcerative Colitis or Crohn's Disease
NCT03478956Phase 1Terminated
- Sponsor
- Roche
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of Etrolizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Roche. Primary endpoints: Maximum Serum Concentration at Day 84, Time to Maximum Serum Concentration at Day 84 and 4 more. Started Mar 2018; status: terminated.
02
Drugs
Etrolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03478956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478956.